# US 2021/0198689 A1 · Multimodal Vector for Dendritic Cell Infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0198689 A1
- Document ID: US20210198689A1
- Status: Published application
- Kind: A1
- Application number: 16/081,014
- Filed: 2017-03-20
- Published: 2021-07-01
- Earliest claimed: 2017-03-20
- Assignees: Nant Holdings IP, LLC; NantCell, Inc.
- Applicants: Nant Holdings IP, LLC; NantCell, Inc.
- Inventors: Patrick Soon-Shiong; Kayvan Niazi; Shahrooz Rabizadeh
- Web page: https://patentgrep.com/patent/US20210198689A1

## CPC

- A61K 39/0011: {Cancer antigens}
- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61K 38/1777: {Integrin superfamily}
- A61K 39/001102: {Receptors, cell surface antigens or cell surface determinants}
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/70525: {ICAM molecules, e.g. CD50, CD54, CD102}
- C07K 14/70532: {B7 molecules, e.g. CD80, CD86}
- C07K 14/70553: {Integrin beta2-subunit-containing molecules, e.g. CD11, CD18}
- C12N 15/86: Viral vectors
- C12N 2710/10041: Use of virus, viral particle or viral elements as a vector
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Recombinant viruses and viral nucleic acids are contemplated that provide to the infected cell various regulatory molecules that stimulate T-cell and NK-cell activity and that suppress inhibition of T-cell and NK-cell activity. Most preferably, the virus and viral nucleic acid will further include a human cancer-associated sequence, and especially a sequence that encodes a plurality of cancer associated antigens, cancer specific antigens, and/or patient and tumor specific neoantigens. Especially preferred regulatory molecules include CD80 (B7.1), CD86 (B7.2), CD54 (ICAM-1/BB2), CD11 (LFA-1), and an inhibitor of CTLA-4.

## Claims

### Claim 1

A recombinant nucleic acid vector, comprising:
a viral genome comprising a recombinant sequence portion encoding a plurality of genes, wherein the recombinant sequence portion is operably coupled to a regulatory sequence to allow for expression of the plurality of genes; and
wherein the plurality of genes encode four distinct stimulatory molecules and an inhibitory ligand for an immune checkpoint receptor; and
wherein the viral genome has at least one mutated or deleted protein coding sequence to reduce immunogenicity of a virus encoded by the viral genome.

### Claim 2 (depends on 1)

The recombinant nucleic acid vector of claim 1 wherein at least one of the four distinct stimulatory molecules is selected form the group consisting of CD80 (B7.1), CD86 (B7.2), CD54 (ICAM-1/BB2), and CD11 (LFA-1).

### Claim 3 (depends on 1)

The recombinant nucleic acid vector of claim 1 wherein at least two of the four distinct stimulatory molecules is selected form the group consisting of CD80 (B7.1), CD86 (B7.2), CD54 (ICAM-1/BB2), and CD11 (LFA-1).

### Claim 4 (depends on 1)

The recombinant nucleic acid vector of claim 1 wherein at least three of the four distinct stimulatory molecules is selected form the group consisting of CD80 (B7.1), CD86 (B7.2), CD54 (ICAM-1/BB2), and CD11 (LFA-1).

### Claim 5 (depends on 1)

The recombinant nucleic acid vector of claim 1 wherein the four distinct stimulatory molecules are CD80 (B7.1), CD86 (B7.2), CD54 (ICAM-1/BB2), and CD11 (LFA-1).

### Claim at position 6

6-13. (canceled)

### Claim 14 (depends on 1)

The recombinant nucleic acid vector of claim 1 wherein the immune checkpoint receptor is CTLA-4 or PD-1, and optionally wherein the inhibitory ligand comprises a transmembrane domain that anchors the ligand to a cell membrane.

### Claim 15 (depends on 1)

The recombinant nucleic acid vector of claim 1 wherein the recombinant sequence portion further comprises a human cancer-associated sequence.

### Claim 16 (depends on 15)

The recombinant nucleic acid vector of claim 15 wherein the human cancer-associated sequence further comprises a trafficking sequence that preferentially directs a gene product encoded by the cancer-associated sequence to a cytoplasmic compartment of a cell hosting the recombinant nucleic acid vector.

### Claim 17 (depends on 15)

The recombinant nucleic acid vector of claim 15 wherein the human cancer-associated sequence further comprises a trafficking sequence that preferentially directs a gene product encoded by the cancer-associated sequence to a lysosomal or endosomal compartment of a cell hosting the recombinant nucleic acid vector.

### Claim 18 (depends on 15)

The recombinant nucleic acid vector of claim 15 wherein the human cancer-associated sequence encodes a protein selected from the group consisting of a cancer associated antigen, a cancer specific antigen, and a patient- and tumor-specific neoantigen.

### Claim 19 (depends on 1)

The recombinant nucleic acid vector of claim 1 wherein the virus is an adenovirus.

### Claim 20 (depends on 19)

The recombinant nucleic acid vector of claim 19 wherein the at least one mutated or deleted protein coding sequence is selected from the group consisting of E1, E2b, and E3.

### Claim 21 (depends on 1)

The recombinant nucleic acid vector of claim 1 wherein the virus is replication deficient.

### Claim at position 15

22-24. (canceled)

### Claim 25 (depends on 1)

A virus comprising the recombinant nucleic acid vector of claim 1.

### Claim 26 (depends on 25)

The virus of claim 25 wherein the virus is a recombination deficient adenovirus lacking the E2b gene.

### Claim 27 (depends on 26)

The virus of claim 26 wherein the four distinct stimulatory molecules are CD80 (B7.1), CD86 (B7.2), CD54 (ICAM-1/BB2), and CD11 (LFA-1), wherein the immune checkpoint receptor is CTLA-4, and wherein the recombinant sequence portion further comprises a human cancer-associated sequence.

### Claim at position 19

28-29. (canceled)

### Claim 30 (depends on 25)

A method of stimulating an immune response in a mammal in need thereof, comprising a step of administering a virus according to claim 25 under a protocol effective to stimulate the immune response.

### Claim 31 (depends on 30)

The method of claim 30 wherein the step of administering is performed by subcutaneous or subdermal injection.

### Claim 32 (depends on 30)

The method of claim 30 further comprising administering a low-dose chemotherapy or a low-dose radiation therapy to the mammal.

### Claim 33 (depends on 32)

The method of claim 32 wherein the low-dose chemotherapy or the low-dose radiation therapy is metronomically administered.
